Understanding Retatrutide's Triple Agonist Mechanism Retatrutide distinguishes itself from earlier incretin-based therapies through its unprecedented activation of three distinct hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon
doi: 10.1186/s13229-016-0109-5 75
The report projects that sales of orforglipron will reach $16 billion in 2031, whereas retatrutide will produce revenue of $30 billion that year, which includes $10 billion in obesity drug sales and $20 billion in diabetes drug sales
So pleased Dr Myhill stocks it
Gradual weight loss helps : rapid loss may lead to more lean mass loss and more side effects
Appetite changes Some individuals experience reduced appetite, which can contribute to weight loss. Headaches and dizziness These symptoms may occur, particularly during the initial stages of therapy. Injection site reactions Redness, swelling, or discomfort at the injection site can happen, but is usually mild. Pancreatitis There have been reports linking GLP-1 receptor agonists to pancreatitis, an inflammation of the pancreas